The estrogen-induced 52K protein secreted by human breast cancer cells is a lysosomal protease recently identified as a pro-cathepsin D by sequencing several cDNA clones isolated from MCF_ cells (Augereau et al., Mol. Endocr.). Using one of these clones, we detected, in MCF 7 cells, a 2.2 kb mRNA whose level was rapidly increased 4-to 10-fold by estradiol, but not by other classes of steroids. Other mitogens, such as epidermal growth factor and insulin, also induced the 2.2 kb mRNA in a dose-dependent manner. Induction with epidermal growth factor was as rapid but was 2-to 3-fold lower than with estradiol. Antiestrogens had no effect on the 52K-cathepsin-D mRNA in MCF ? cells, but became estrogen agonists in two antiestrogenresistant sublines R, 7 and LY2. The use of transcription and translation inhibitors and nuclear run-on experiments indicate that estradiol enhances transcription of the 52K-cathepsin-D gene in MCF™ cells.
INTRODUCTION
A large proportion of human breast cancers is characterized by its ability to exhibit metastasis and to be regulated by estrogens (1) . Estrogens stimulate growth of metastatic breast cancer cell lines containing estrogen receptors (MCF 7 , T 4? D...) (2) , following the induction of several proteins (3 and ref. therein) . The proteins that are secreted, such as growth factors (4) and proteases (5) , are particularly interesting since they may stimulate tumor growth and invasion by autocrine and paracrine mechanisms (6) . They are also generally produced, but not estrogen-regulated, in estrogen-receptor negative cancers. We have extensively studied a secreted 52K glycoprotein (7) which was found to be mitogenic in vitro (8) . The protein has recently been identified as a pro-cathepsin-D-like protease (52K-cath-D) that can degrade extracellular matrix (9, 10) . The level of regulation of this protease remained unknown, however, and the only gene (pS2) (11) , shown to be transcriptionally regulated by estrogens in these cells (12) , corresponds to a 7-10K protein of unknown function.
Using monoclonal antibodies and a 36-mer oligonucleotide synthesized from the N-terminal sequence of the protein, we have isolated from MCF_ libraries four cDNA clones corresponding to a 2,039 bp coding sequence (13) that is more than 99% identical to that of normal kidney cathepsin D (14) .
In the present study, we used the 52K-9 cDNA clone to analyze the hormonal regulation of the 52K-cath-D mRNA. We show that estrogens, but not other steroids, rapidly induce 52K-cath-D mRNA by stimulating transcription. Moreover, it was found that other mitogens such as epidermal growth factor (EGF) or insulin can also rapidly increase the level of 52K-cath-D mRNA.
MATERIALS AND METHODS

Cell culture
MCF 7 cells (15) were obtained from the Michigan Cancer Foundation and were routinely maintained in T75 flasks in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum (Gibco) and 0.6 jig/ml bovine insulin (Collaborative Research). To test the effect of hormones on RNA accumulation, slightly confluent MCF_ cells were plated out in T75 flasks (10-fold dilution) in the same medium for 2 days. They were then stripped of hormones with 10 % serum treated with dextran-coated charcoal in phenol-red-free DMEM.
The medium was changed every 2 days after two washes with phosphate-buffered saline. After at least 5 days of withdrawal, estradiol or other steroids were added to cells in an ethanol solution (final concentration of ethanol 0.1 %) and solvent alone was added to control cells. For stimulation by insulin and mouse EGF (Collaborative Research), cells were cultured and stripped under the same conditions but without Insulin.
The two antiestrogen-resistant variants of the MCF_ cell line, R 27 (16) and LY2 (17) , selected for their resistance to the growth inhibitory effects of tamoxifen and LY117018, respectively, were obtained from Marc Lippman (National Cancer Institute, Bethesda, Maryland, USA). R_ 7 cells were maintained in DMEM with 10 % fetal calf serum treated with dextran-coated charcoal, 0.6 ng/ml insulin, and 1 nM tamoxifen. They were stripped of estrogens and tamoxifen by culturing for 14 days in hormone-free medium, as in the case of MCF 7 cells. During this time, they were passaged once and the medium was changed every 3 days.
LY2 cells were maintained in DMEM with 5% charcoal-stripped calf serum and 0.6 ng/ml insulin. Stimulation by estradiol (1 nM) or antiestrogen (1 |iM tamoxifen or its high-affinity metabolite 1 nM 4-hydroxytamoxifen) was performed as described (18) .
RNA preparation, Northern blot analysis
Total RNA was extracted from MCF_ human breast cancer cells by the method of Auffray and Rougeon (19) . RNA was electrophoresed on a 1% agarose formaldehyde denaturing gel and then transferred to nitrocellulose. The double-stranded cDNAs 32 in the vectors were P-labeled, using random primers (20) , to q a specific activity of 1 to 3 x 10 dpm per tig. Filters were prehybridized for 24 h at room temperature and then hybridized in 50% formamide for 3 days at 37°C (2 x 10 6 cpm/ml).
Hybridization solutions were prepared as described (18) .
Washing was done in 2 x SSC, 0.1% SDS (1 x SSC is 150 mM NaCl, 15 mM sodium citrate) once for 20 min at room temperature and twice for 1 h at 65°C, and the filters were autoradiographed for 5 to 20 h at -70°C using intensifying screens. Immunoenzymatic assay of the secreted 52K-cath-D was performed by a double-determinant solid-phase assay (21, 22) .
Nuclear run-on transcription assay
Nuclear transcription was performed according to Brown et al. (12) with modifications. Nuclei were isolated from MCF 7 cells treated or not with 10 nM estradiol and nascent RNA transcripts initiated in vivo were elongated in vitro in the presence of | P | UTP (400 Ci/mmole ; Amersham) for 45 min at 30°C. Labeled RNA was then extracted with phenol-chloroform after DNAse and proteinase K treatment.
The unincorporated nucleotides were eliminated by precipitation twice with ethanol and ammonium acetate. Seven-|ig of denatured plasmids were spotted onto nitrocellulose filters using a BRL Dot blot apparatus. We used 52K-9 cDNA to quantify the newly synthesized 52K-cath-D RNA, pS2 cDNA as a positive control of transcriptional regulation by estradiol, 36B4 and C3 (23) cDNAs (which correspond to poly A+ RNAs unaffected by estradiol in MCF_ cells) as constant controls, and the M13 vector alone to evaluate nonspecific hybridization. Prehybridization was done for 2 days at 37°C in 50 mM NaP04, pH7, 750 mM NaCl, 50% formamide, 0,5% SDS, 2 mM EDTA, 10X Denhart's, 1 tig/ml poly (A) and 500 ug/ml denatured salmon sperm DNA. Hybridization was done in the same solution for 4 days at 37°C, with the same amount of labeled RNA (up to 2 x 10 cpm) from control or Entreated cells. Filters were washed, RNAse A treated and finally autoradiographed for 2 days. The relative intensity of a spot evaluated by densitometric scanning was shown to be proportional to the amount of sample hybridized (data not shown).
RESULTS
Effect of estradlol and growth factors on the levels of 52K-cath-D RNA
The 52K-9 cDNA probe corresponds to most of the coding sequence of normal cathepsin D mRNA ( Fig. la) and hybridized with a 2.2 kb RNA of MCF ? cells, which corresponds to the size of the cathepsin D mRNA in normal tissue (14) . The level of this 2.2 kb RNA was increased 6-to 8-fold by estradiol (E 2 ) compared to the estrogen-independent 36B4 mRNA ( Fig. lb and c) . The 0.6 kb pS2 mRNA (11) was also significantly increased by estradiol as expected (Fig. lc) . Similar results were obtained with poly A+ RNA (not shown). The 52K-9 probe also detected a less abundant 52K-cath-D RNA species of about 4.5 kb which was also regulated by estradiol. The significance of this 4.5 kb RNA is not known but it could correspond to a precursor of the 2.2 kb mRNA since its increase was transient and more rapid (data not shown).
Other classes of steroid hormones, i.e. progestin (R5020) and glucocorticoid (dexamethasone) increased the 2.2 kb mRNA by no more than 10% (Fig. lb) . The androgen dihydrotestosterone was inactive at 10 nM but was active at micromolar concentrations previously shown to induce the secreted 52K-cath-D protein via the estrogen receptor (7).
The 52K-cath-D mRNA level was, however, increased by mitogens other than estradiol. EGF and insulin at concentrations previously shown to stimulate the growth of MCF_ cells (24) , increased the level of 52K-cath-D RNA 4-and 2-fold, respectively (Fig. lc) . These effects were also confirmed at the protein level by the increase in secreted and cellular 52K-cath-D measured by immunoenzymatic assay (21) (Fig. 3 and D. Derocq, unpublished experiments). Using radiocompetition for the estrogen receptor, we checked that EGF and insulin preparations contained no estrogen-like compounds (not shown). (14) . The open boxes stand for the coding sequence and correspond to the signal sequence (1), the pro-sequence (2) and the sequence of the mature enzyme (3 and 4). Coordinates of the coding sequence of normal cathepsin D (from 52 to 1287) and of the terminal nucleotides of the 52K-9 clone are indicated. The internal deletion (dotted line from 192 to 295) in this cDNA clone is a cloning artefact. Sequence analyses of 52K-9 and other clones (13) indicate a 99% homology with normal kidney cathepsin-D (14) .
b. MCF_ cells were stripped of estrogens and then incubated for 3 days either in the absence of hormone (C) or with the indicated concentrations of estradiol (Ep), dexamethasone (Dex), a synthetic progestin (R5O2O), or dihydrotestosterone (DHT). Total RNA (40 tig) was analyzed by Northern blotting as described in Materials and Methods. Hybridization was done with the 52K-9 cDNA to probe 52K-cath-D mRNAs and with 36B4 cDNA, which detects an RNA species unaffected by estradiol (11) .
c. MCF_ cells were stripped of steroids for 7 days without adding insulin. They were then treated for 3 days with E p at 10 nM, insulin (Ins) at 50 and 100 nM and EGF at 4 and 8 nM. Total RNA was analyzed as in b and also probed with pS2 cDNA, which corresponds to an estrogen-induced mRNA in MCF_ cells (11) . The lengths of the RNA species detected are indicated in kilobases (kb). level of 52K-cath-D mRNA was greater than that of insulin, whereas both mitogens had a similar effect on pS2 mRNA, suggesting a difference in the hormonal sensitivity of the corresponding genes.
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We then studied the induction of the 52K-cath-D RNA in MCF ? cells after treatment for different times with estradiol and EGF.
The level of the 2.2 kb 52K-cath-D RNA increased rapidly within 2-6 h following the addition of estradiol and MCF_ cells were treated for 3 days as in Fig. 2 with increasing concentrations of estradiol (E ? ), tamoxifen (T) (a) or EGF (b). The levels of 52K-cath-D mRlm (full symbols) were determined after hybridization with 52K-9 and 36B4 cDNAs as described in Fig. 2 .
The amount of secreted 52K protein accumulated in the medium at the end of treatment (open symbols) was determined using an immunometric assay (21, 22) .
Results are expressed as percentages of the maximum.
was nearly maximal after 24 h (Fig. 2a) . This increase anticipated that of the intracellular protein (25) and the 52K-cath-D protein secreted into the culture media, which increased slowly for 16 h of treatment and more rapidly thereafter (not shown). The half-maximal induction with EGF was also obtained before 10 h of treatment but its effect at 2 h was even higher than that of estradiol (Fig. 2b) . Fig. 3 shows that the induction of 52K-cath-D mRNA and the increase in the MCF_ cells and two antiestrogen-resistant variants, R 2? and LY2, were stripped of hormones and treated for 3 days wirn 1 nM estradiol (E_), 1 nM tamoxifen (T), 1 nM OH-Tamoxifen (OHT) or with solvent alone. The levels of 52K-cath-D mRNAs (S) and secreted 52K-cath-D protein (•) were determined as described in Fig. 3 .
Results are expressed as percentages of the induction obtained with estradiol.
secreted 52K-cath-D were obtained at the same physiological concentrations of estradiol and EGF.
These effects are consistent with a progressive occupation and activation of the estrogen and EGF receptor sites, respectively.
Effect of antiestrogens on MCF_ cells and antiestrogenresistant variants
In MCF ? cells, neither tamoxifen (Fig. 3a) nor hydroxytamoxifen (not shown), which is its high-affinity metabolite, b. MCF_ cells were stripped of estrogens and treated for 2 days with 10 nM estradiol or with solvent alone (control). Cells were then treated with 5 n g/ml actinomycin D for the indicated times.
In both cases, the 2.2 kb cathepsin D mRNA level was assayed in total RNA as described in Fig. lb. hydroxytamoxifen (1 nM) to a level that was similar or at least 40% of that obtained in parallel with estradiol (Fig. 4) . The same antiestrogens had little or no effect on the 2.2 kb mRNA in wild-type MCF 7 cells.
The secreted 52K-cath-D assayed in the same experiment was induced by antiestrogens in R 27 cells but not in LY2 cells, in accordance with previous studies (18, 26, 27) . The dissociated effects observed in LY2 cells, in which the antiestrogens induced the 2.2 kb mRNA but not the secreted 52K-cath-D is not yet explained, however they suggest an additional effect of antiestrogens on protein maturation and/or secretion.
Evidence for a regulation of 52K-cath-D gene transcription by estradiol
To test whether the induction of 52K-cath-D mRNA is a primary effect of estradiol, we first tested the effect of a protein synthesis inhibitor. MCF_ cells were pretreated for 1 h with 50 nM cycloheximide, which was found to reduce protein synthesis by at least 96% (data not shown), before adding 10 nM estradiol for 8 h with cyeloheximide still present. The induction of 2.2 kb RNA was not significantly reduced (Fig. 5a ) suggesting that it does not depend on the induction of another protein. We then analyzed the stability of 52K-cath-D mRNA in the presence or absence of estradiol, while its synthesis was blocked by actinomycin D. The level of 2.2 kb mRNA was stable after 10 h of treatment with actinomycin D, in the absence of hormone (control). Pretreatment for 48 h with estradiol did not significantly affect this stability (Fig. 5b) . In another experiment, the increased level of 52K-cath-D mRNA produced by 11 h treatment with estradiol was totally abolished when actinomycin D (5 ug/ml) was added together with the hormone (not shown).
This effect of actinomycin D suggested a transcriptional regulation by estradiol.
We then studied the effect of estradiol on the transcription of the 52K-cath-D gene in isolated nuclei. Following treatment of cells with estradiol, the nascent mRNAs initiated in vivo were elongated in vitro in isolated nuclei in op the presence of | P|UTP. Labeled RNAs were then hybridized to 52K-9, pS2, or control cDNAs spotted on nitrocellulose. As shown in Fig. 6a, 52K -cath-D gene transcription was increased 4-fold by incubation with fetal calf serum for 24 h and 2-fold following 3 h of treatment by estradiol. Time-course experiments indicated that the stimulation of 52K-cath-D gene transcription was rapid (30 min), peaked at 1 h and remained stable until 24 h.
In the same experiments, pS2 gene transcription was enhanced 4-fold 1 h after estradiol addition. The transcription of two genes known to be unaffected by estradiol in MCF ? cells, i.e. 36B4 (Fig. 6b) and C3 (not shown) was constant with time. These results indicate that estradiol directly stimulates 52K-cath-D gene transcription.
DISCUSSION
The hormonal regulation of the 2.2 kb 52K-cath-D mRNA was studied in MCF™ breast cancer cells and three sets of information were obtained :
1) The regulation of 52K-cath-D mRNA by estradiol is at least partly due to stimulation of transcription.
We cannot totally exclude a post-transcriptional effect of estradiol since the maximal intensity of the transcription effect (2-3-fold) was lower than the increased accumulation of mRNA (4-10-fold). However, in our run-on experiments, estradiol increased by only 4-fold, pS2 transcription which was previously reported to be increased by 8-fold (12) . Cathepsin D is therefore, after the pS2 protein, the second example of a gene transcriptionally regulated by estrogens in human breast cancer cells. Three other mRNAs have been shown to accumulate following estradiol treatment, i.e. progesterone receptor mRNA (E. Milgrom, personal communication), and thymidine kinase and dihydrofolate reductase mRNAs (28) determine this mechanism and to compare the estrogenresponsive elements with those of other estrogen-regulated genes. There are general differences between the regulation of pS2 and 52K-cath-D in breast cancer cells. The expression of pS2 only occurs in estrogen-receptor-positive cells, whereas cathepsin D is also produced in estrogen-receptor-negative breast cancer (13) . Both genes are also regulated differently in antiestrogen-resistant cells (see below).
2) The different effects of antiestrogens on the synthesis of the 2.2 kb-cath-D mRNA in antiestrogen-sensitive and -resistant cells confirm previous findings based on the quantification of secreted 52K-cath-D (18, 26) . The discrepancy observed in the LY2 subline, where antiestrogen stimulates mRNA-cathepsin D accumulation but not 52K-cath-D secretion (27) suggests an additional level of regulation for secretion. It would thus appear that in the three antiestrogen-resistant sublines (R 2? , RTx6 and LY2 derived from MCF 7 cells), the estrogen receptor-antiestrogen complex is able to stimulate the accumulation of 52K-cath-D mRNA, but is unable to do so in MCF ? wild-type cells. The effects of antiestrogens vary according to different estrogen-induced responses. Progesterone receptors are induced in both antiestrogen-sensitive and -resistant cells by tamoxifen whereas pS2 mRNA and the 160K protein are not affected in any of these cells (18) . The induction of 52K-cath-D mRNA thus appears to be the only known response associated with antiestrogen-resistant breast cancer.
The reasons for the induction of cath-D mRNA by tamoxifen in resistant cells is unknown. Alterations during procedures for subline selection may affect estrogen receptors or the structure of estrogen-responsive elements.
3) The 52K-cath-D mRNA is also induced by other types of mitogens, such as insulin and EGF, suggesting that its regulation may be complex and controlled by different promoter elements that are sensitive to different hormones. EGF-like or IGFI growth factors have also been reported to be induced by estrogens in the same cells (4) and these factors or other mitogens might therefore mediate the induction of 52K-cath-D mRNA by estrogens. However, this possibility is unlikely since the rapid stimulation of 52K-cath-D gene transcription and the resistance to cycloheximide, both of which suggest that the regulation of 52K-cath-D mRNA by estrogens is not mediated by growth factors.. The mechanism (direct or indirect) by which insulin or EGF operate has not yet been investigated. Further studies are needed to determine the biological significance of protease induction by growth factors. Moreover, induction of 52K-cath-D mRNA by mitogens such as estrogens and growth factors is in agreement with clinical studies indicating that tissue accumulation of this protease is associated with cell proliferation (29) . Another example of a growth-factor-induced cathepsin involved in carcinogenesis is cathepsin-L (or major excreted protein : MEP). In mouse BALB/c 3T3 cells, cathepsin-L gene transcription increases after treatment with plateletderived growth factor (PDGF, but not EGF, IGF1 and insulin), tumor promoter, or after transformation by oncogenes (30) . In contrast with the effect of estrogens on cathepsin-D mRNA, the induction of cathepsin-L mRNA by PDGF requires de novo protein synthesis.
Recently, using a different approach, Westley and May have also shown that estradiol increases the level of cathepsin D RNA in the ZR75-1 estrogen-receptor-positive cell line (31) . Their results are in accordance with the present results in MCF ? cells, but the mechanism of induction was not determined and the effect of growth factors was not investigated. Estrogens clearly induce the 52K-cath-D mRNA in human breast cancer cells in culture, but their effect on normal mammary cells or other estrogen target tissues has not been demonstrated. Normal mammary cells in primary culture may not contain a sufficient amount of estrogen receptors to stimulate cathepsin D expression (G. Cavalie, F. Capony, unpublished results). However, in rat uteri, which contain high level of estrogen receptors, progestins rather than estradiol increase cathepsin D activity and synthesis (32) . Further studies will be needed to determine whether estrogen induction of the cathepsin D gene characterizes mammary cells or transformed cells. Among the proteins shown to be regulated by estrogens at the mRNA level in MCF cells (4, 11, 28, 33) , 52K-cath-D is the first example of a protease that is transcriptionally regulated by estrogens. This induction may be important in the process of mammary carcinogenesis and metastasis since the resulting pro-enzyme is also secreted in excess by breast cancer cells compared to normal cells (25 and F.
Capony et al., in preparation) and may therefore act either directly as a classical growth factor or indirectly by its proteolytic activity. The biological activity of this protease will be more directly demonstrated by transfection experiments. These investigations should increase our understanding of the role of estrogens and of cathepsin D in mammary carcinogenesis, and that of the mechanism by which estrogens and antiestrogens regulate gene expression.
